Discovery of Competitive and Noncompetitive Ligands of the Organic Cation Transporter 1 (OCT1; SLC22A1)

被引:51
|
作者
Chen, Eugene C. [1 ,6 ]
Khuri, Natalia [1 ,7 ]
Liang, Xiaomin [1 ]
Stecula, Adrian [1 ]
Chien, Huan-Chieh [1 ]
Yee, Sook Wah [1 ]
Huang, Yong [2 ]
Sali, Andrej [1 ,3 ,4 ]
Giacomini, Kathleen M. [1 ,3 ,4 ,5 ]
机构
[1] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA
[2] Optivia Biotechnol, Menlo Pk, CA 94025 USA
[3] Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94158 USA
[4] Univ Calif San Francisco, California Inst Quantitat Biosci, San Francisco, CA 94158 USA
[5] Univ Calif San Francisco, Inst Human Genet, San Francisco, CA 94143 USA
[6] Genentech Inc, Dept Metab & Pharmacokinet, San Francisco, CA 94080 USA
[7] Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA
基金
美国国家卫生研究院;
关键词
SUBSTRATE-BINDING REGION; DRUG-DRUG INTERACTIONS; AMINO-ACIDS; CRYSTAL-STRUCTURE; ENDOGENOUS AMINE; HIGH-THROUGHPUT; HOCT1; INHIBITION; PARKINSONISM; METFORMIN;
D O I
10.1021/acs.jmedchem.6b01317
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Organic cation transporter 1 (OCT1) plays a critical role in the hepatocellular uptake of structurally diverse endogenous compounds and xenobiotics. Here we identified competitive and noncompetitive OCT1-interacting ligands in a library of 1780 prescription drugs by combining in silico and in vitro methods. Ligands were predicted by docking against a comparative model based on a eukaryotic homologue. In parallel, high throughput screening (HTS) was conducted using the fluorescent probe substrate ASP(+) in cells overexpressing human OCT1. Thirty competitive OCT1 ligands, defined as ligands predicted in silico as well as found by HTS, were identified. Of the 167 ligands identified by HTS, five were predicted to potentially cause clinical drug interactions. Finally, virtual screening of 29 332 metabolites predicted 146 competitive OCT1 ligands, of which an endogenous neurotoxin, 1-benzyl-1,2,3,4-tetrahydroisoquinoline, was experimentally validated. In conclusion, by combining docking and in vitro HTS, competitive and noncompetitive ligands of OCT1 can be predicted.
引用
收藏
页码:2685 / 2696
页数:12
相关论文
共 50 条
  • [1] Evaluation of organic cation transporter 1 (OCT1, SLC22A1) as transporter for sorafenib
    Neul, Claudia
    Baker, Sharyn D.
    Sparreboom, Alex
    Schaeffeler, Elke
    Laufer, Stefan
    Schwab, Matthias
    Nies, Anne T.
    [J]. CANCER RESEARCH, 2016, 76
  • [2] ORGANIC CATION TRANSPORTER 1 (OCT1; SLC22A1) MODULATES HEPATIC ENERGY METABOLISM
    Liang, X.
    Luo, Q.
    Yee, S.
    Chen, E. C.
    Chien, H. -C.
    King, S.
    Giacomini, K. M.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S8 - S8
  • [3] Impact of Promoter Polymorphisms on the Transcriptional Regulation of the Organic Cation Transporter OCT1 (SLC22A1)
    Bokelmann, Kristin
    Brockmoeller, Juergen
    Tzvetkov, Mladen, V
    [J]. JOURNAL OF PERSONALIZED MEDICINE, 2018, 8 (04):
  • [4] Regulation of basal core promoter activity of human organic cation transporter 1 (OCT1/SLC22A1)
    Kajiwara, Moto
    Terada, Tomohiro
    Asaka, Jun-ichi
    Aoki, Masayo
    Katsura, Toshiya
    Ikai, Iwao
    Inui, Ken-ichi
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2008, 295 (06): : G1211 - G1216
  • [5] Sorafenib therapy for treatment of liver cancer is independent from organic cation transporter 1 (OCT1/SLC22A1)
    Chen, M.
    Neul, C.
    Schaeffeler, E.
    Frisch, F.
    Winter, S.
    Schwab, M.
    Koepsell, H.
    Hu, S.
    Laufer, S.
    Baker, S. D.
    Sparreboom, A.
    Nies, A. T.
    [J]. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2019, 392 : S17 - S18
  • [6] INTERINDIVIDUAL VARIABILITY OF ORGANIC CATION TRANSPORTER OCT1 (SLC22A1) AND OCT3 (SLC22A3) EXPRESSION IN HUMAN LIVER
    Nies, Anne T.
    Schaeffeler, Elke
    Klein, Kathrin
    Zanger, Ulrich M.
    Kerb, Reinhold
    Koepsell, Hermann
    Keppler, Dietrich
    Schwab, Matthias
    [J]. DRUG METABOLISM REVIEWS, 2008, 40 : 153 - 154
  • [7] DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma
    Schaeffeler, Elke
    Hellerbrand, Claus
    Nies, Anne T.
    Winter, Stefan
    Kruck, Stephan
    Hofmann, Ute
    van der Kuip, Heiko
    Zanger, Ulrich M.
    Koepsell, Hermann
    Schwab, Matthias
    [J]. GENOME MEDICINE, 2011, 3
  • [8] DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma
    Elke Schaeffeler
    Claus Hellerbrand
    Anne T Nies
    Stefan Winter
    Stephan Kruck
    Ute Hofmann
    Heiko van der Kuip
    Ulrich M Zanger
    Hermann Koepsell
    Matthias Schwab
    [J]. Genome Medicine, 3
  • [9] Interactions of antiretroviral drugs with the SLC22A1 (OCT1) drug transporter
    Moss, Darren M.
    Liptrott, Neill J.
    Siccardi, Marco
    Owen, Andrew
    [J]. FRONTIERS IN PHARMACOLOGY, 2015, 6
  • [10] STRUCTURAL REQUIREMENTS FOR DRUG INHIBITION OF THE HUMAN ORGANIC CATION TRANSPORT PROTEIN OCT1 (SLC22A1)
    Ahlin, Gustav
    Karlsson, Johan
    Pedersen, Jenny
    Gustavsson, Lena B. M.
    Larsson, Rolf
    Matsson, Par
    Norinder, Ulf
    Bergstrom, Christel A. S.
    Artursson, Per
    [J]. DRUG METABOLISM REVIEWS, 2008, 40 : 158 - 159